Govt wants to beef up Drug Price Order, revisits it

Seeks to make it more efficient both for consumers and the industry

<a href="http://www.shutterstock.com/pic-228848833/stock-photo-pills-drug.html" target="_blank">Image</a> via Shutterstock
Press Trust of India New Delhi
Last Updated : Jul 26 2015 | 1:11 PM IST
The government is reviewing the Drug (Prices Control) Order, 2013, to sort out implementation issues and make it more efficient -- both for consumers and the industry.

"We are discussing...And will keep discussing to see if there are any anomalies in the order and at the same time, we want to make the regulations more clear," sources said.

ALSO READ: NPPA adds 39 more drugs to the controlled list

The idea is to make the price control order easy to implement, they added.

The government, according to the sources, has sought inputs on DPCO from all stakeholders, including the industry and the civil society.

Meanwhile, a task force constituted by the Department of Pharmaceuticals has also recommended review of DPCO 2013.

ALSO READ: NPPA directs pharma companies to pass on lower excise duty benefit

"There is a need to review the implementation of DPCO 2013 to resolve genuine practical problems of implementation. The government may implement a predictable and stable price control mechanism through a consultative approach with the industry," the task force had said in its report submitted last month.

Pointing to the shortage of drug inspectors, the task force had suggested one drug inspector per 50 manufacturing units and one inspector per 200 sales/distribution outlets.

As stipulated under DPCO 2013, the National Pharmaceutical Pricing Authority (NPPA) fixes the ceiling price of essential medicines of schedule-I.


So far, the authority has fixed the ceiling price of 530 formulations from the list. And no one is authorised to sell any scheduled formulation (medicine) to a consumer at a price higher than the one notified by NPPA under the order.

While fixing the ceiling price, 16 per cent margin is allowed for retailers. For non-scheduled formulations, there is no control over the launch price.

In respect of medicines not under price control, manufacturers are allowed to increase the maximum retail price (MRP) by 10 per cent annually.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Jul 26 2015 | 12:02 PM IST

Next Story